[{"id":"b64bb555-e821-4861-b6f7-f3589e290e8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03012100","created_at":"2021-01-18T14:49:14.234Z","updated_at":"2024-07-02T16:35:57.635Z","phase":"Phase 2","brief_title":"Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer","source_id_and_acronym":"NCT03012100","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • FR Alpha Peptide Vaccine • Leukine (sargramostim) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 03/31/2017","start_date":" 03/31/2017","primary_txt":" Primary completion: 08/30/2022","primary_completion_date":" 08/30/2022","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2023-01-13"}]